SCHEMBL759362

SCHEMBL759362

Nc1ccc(CCNc2ncnc3sc4c(c23)CCCC4)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.63
MAPT P10636 3/20 0.63
TSHR P16473 3/20 0.63
HPGD P15428 2/20 0.63
MAPK1 P28482 2/20 0.63
HTT P42858 2/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
PDE5A O76074 1/20 0.61
CSNK2A2 P19784 1/20 0.61
CSNK2B P67870 1/20 0.61
CSNK2A1 P68400 1/20 0.61
PTGS2 P35354 1/20 0.57
GFER P55789 1/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 3/20 0.56
GAA P10253 2/20 0.56
REN P00797 1/20 0.55
MKNK1 Q9BUB5 2/20 0.55
FGFR1 P11362 1/20 0.55
MEN1 O00255 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13164977 0.85 MAPT (0.69) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL925205 0.82 MKNK1 (0.79) LMNAMAPTHPGDMAPK1HTT
SCHEMBL1604847 0.81 CSNK2A2 (0.67) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL735116 0.80 PTGS2 (0.70) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL13164911 0.80 CSNK2A2 (0.73) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL757854 0.80 PTGS2 (0.69) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL759953 0.80 PTGS2 (0.69) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL14623890 0.79 CSNK2A2 (0.65) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL13431519 0.79 LMNA (0.62) LMNAMAPTTSHRHPGDMAPK1
SCHEMBL13165097 0.77 LMNA (1.00) LMNAMAPTTSHRHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276346-B1 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS NAT HEALTH RESEARCH INSTITUTES (TW) 2016-11-23 EP disclosed
CN-102014627-B Fused bicyclic pyrimidine compounds as aurora kinase inhibitors NATIONAL HEALTH RESEARCH INSTITUTES (CN) 2014-10-29 CN disclosed
US-8138194-B2 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2012-03-20 US disclosed
US-8138194-B2 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2012-03-20 US disclosed
CN-102014627-A Fused bicyclic pyrimidine compounds as aurora kinase inhibitors NAT HEALTH RESEARCH INSTITUTES 2011-04-13 CN disclosed
US-20090275533-A1 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2009-11-05 US disclosed
US-20090275533-A1 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2009-11-05 US disclosed
WO-2009134658-A2 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275533-A1 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS AURKB, AURKA, AURKC LMNA 821/4885MAPT 2833/4885TSHR 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.